Connect with us

Technology

Fresenius Medical Care introduces TherapyWise™ analytics for kidney replacement therapy

Published

on

Cloud-based platform provides retrospective, program-level insight into kidney replacement therapy delivered in acute and hospital critical care settingsAvailable within NxStage® System One™ with NxView™ 4.0, Fresenius Medical Care’s FDA 510(k)-cleared software platform for kidney replacement therapy in the United StatesAggregates existing therapy and device data to support identification of trends related to workflow interruptions, alarm burden, and variability

BAD HOMBURG, Germany, July 20, 2026 /PRNewswire/ — Fresenius Medical Care, the world’s leading provider of products and services for individuals with renal diseases, today announced the introduction of TherapyWise™, a cloud-based analytics capability available within NxView™ 4.0, the Company’s FDA 510(k)-cleared software platform for use with the NxStage® System One™ in the United States. TherapyWise is designed to provide retrospective, program-level insight into kidney replacement therapy (KRT) delivered in acute and hospital critical care settings.

Kidney replacement therapy in the Intensive Care Unit (ICU) generates large volumes of clinical and operational data, yet trends related to therapy delivery, workflow interruptions, and alarm frequency can be difficult to assess without standardized metrics and aggregated views. TherapyWise consolidates existing data generated at the point of care and presents longitudinal summaries intended to support oversight of KRT programs across ICU units and time periods.

“Digital solutions play an increasingly important role in how critical care teams understand and manage complex therapies,” said Joe Turk, Chief Executive Officer of Care Enablement at Fresenius Medical Care. “TherapyWise reflects our continued focus on innovation in critical care by applying data analytics. This helps hospital and clinical leaders gain visibility into how kidney replacement therapy is delivered across their organizations, supporting informed discussions around workflow, consistency, and quality improvement.”

TherapyWise works by securely transmitting data from the NxStage System One with NxView to a cloud‑based platform, where information is aggregated and displayed across predefined performance indicators. These include program‑level metrics including average delivered dose compared with set dose, average treatment time per cartridge, and alarm frequency trends. The software is intended to support retrospective review and program oversight and is not designed for real‑time, patient‑specific clinical decision‑making, which remains the responsibility of attending clinicians.

TherapyWise is part of Fresenius Medical Care’s NxView 4.0 software platform and broader critical care portfolio, which combines digital infrastructure, clinical expertise, and secure data management to support hospital teams responsible for kidney replacement therapy programs.

To learn more about TherapyWise, please visit https://freseniusmedicalcare.com/en-us/products/critical-care/therapywise/.

About Fresenius Medical Care:
Fresenius Medical Care is the world’s leading provider of products and services for individuals with renal diseases of which around 4.5 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,539 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approx. 290,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).

For more information visit the company’s website at www.freseniusmedicalcare.com.

Disclaimer:
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care’s reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care does not undertake any responsibility to update the forward-looking statements in this release.

Media contact
Christine Peters
T +49 160 60 66 770
christine.peters@freseniusmedicalcare.com 

Kirsten Stratton
T +1 781 929 8096
kirsten.stratton@freseniusmedicalcare.com 

Contact for analysts and investors
Dr. Dominik Heger
T +49 6172 609 2525
dominik.heger@freseniusmedicalcare.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/fresenius-medical-care-introduces-therapywise-analytics-for-kidney-replacement-therapy-302829320.html

SOURCE Fresenius Medical Care Holdings, Inc.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

EMERGE Reports Strong Preliminary Q2 Results

Published

on

By

TORONTO, July 22, 2026 /CNW/ — EMERGE Commerce Ltd. (TSXV: ECOM) (“EMERGE” or the “Company”), an acquirer and operator of profitable e-commerce brands and technologies, is pleased to provide preliminary unaudited results for the second quarter ended June 30, 2026.

Select Preliminary Q2 2026 Financial Highlights (vs. Q2 2025):

Revenue expected to be between $9.0M and $9.1M vs. $8.5MGross margin expected to be approximately 39% vs. 36%Adj. EBITDA(1) expected to be between $1M and $1.1M vs. $958KCash Position grew to $4.8M (June 30, 2026) vs. $3.5M (June 30, 2025) and $4.1M (March 31, 2026)

EMERGE expects to file its full Q2 results in late August 2026.

Preliminary Unaudited Financial Information

The financial and operating results included in this news release are based on preliminary unaudited estimated results which have not yet been finalized. These estimated results are subject to change upon completion of the Q2 2026 financial statements and such changes could be material due to, among other things, the completion of EMERGE’s financial closing procedures, final adjustments, and other developments that may arise between now and the time the financial results are finalized. Accordingly, such estimated results are forward-looking statements (as defined below) within the meaning of applicable securities legislation and are subject to the limitations and risks described under “Forward-Looking Statements” below. Unless otherwise noted, all amounts are in Canadian dollars.

About EMERGE

EMERGE Commerce (TSXV: ECOM) is a disciplined acquirer and operator of profitable e-commerce brands and technologies across Direct-to Consumer (“D2C”) and Business-to-Business (“B2B”) segments. Our D2C portfolio spans our Grocery and Golf verticals. truLOCAL is our flagship Canadian meat and seafood subscription service. Our Golf vertical includes UnderPar (discounted golf experiences), JustGolfStuff and Tee 2 Green (discounted apparel and equipment). EMERGE B2B houses Viral Loops, our referral marketing platform.

Follow EMERGE:
LinkedIn | X | Instagram | Facebook

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

(1) Non-GAAP Measures

This press release makes reference to certain non-GAAP measures. These non-GAAP measures are not recognized measures under IFRS, do not have a standardized meaning prescribed by IFRS and are therefore unlikely to be comparable to similar measures presented by other companies. Rather, these measures are provided as additional information to complement those IFRS measures by providing a further understanding of results of operations from management’s perspective. Accordingly, they should not be considered in isolation nor as a substitute for analysis of the financial information of the Company reported under IFRS. EBITDA, and Adjusted EBITDA should not be construed as alternatives to revenue or net income/loss determined in accordance with IFRS. EBITDA and Adjusted EBITDA do not have any standardized meaning under IFRS and therefore may not be comparable to similar measures presented by other issuers.

Earnings before interest, taxes, depreciation and amortization (“EBITDA”) and Adjusted EBITDA as defined by management means earnings before interest and financing costs, income taxes, depreciation and amortization, transaction costs, foreign exchange gains/losses, discontinued operations, fair value increments on inventory included in cost of sales, unrealized gains/losses on contingent consideration and share-based compensation. Management believes that Adjusted EBITDA is a useful measure because it provides information about the operating and financial performance of EMERGE and its ability to generate ongoing operating cash flow to fund future working capital needs and fund future capital expenditures or acquisitions.

A reconciliation of the adjusted measures is included in the Company’s management discussion & analysis for the three months ended March 31, 2026 in the section “Non-GAAP Financial Measures” available through SEDAR at www.sedar.com.

Notice regarding forward-looking statements

This press release may contain certain forward-looking information and statements (“forward-looking information”) within the meaning of applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words “believes”, “anticipates”, “plans”, “intends”, “will”, “should”, “expects”, “continue”, “estimate”, “forecasts” and other similar expressions. Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements. The Company undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of the Company, its securities, or financial or operating results (as applicable). Although the Company believes that the expectations reflected in forward-looking information in this press release are reasonable, such forward-looking information has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond the Company’s control, including the risk factors discussed in the Company’s MD&A which is incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and is made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise. Unless otherwise noted, all amounts are in Canadian dollars.

On Behalf of the Board
Ghassan Halazon
Director, President, and CEO
EMERGE Commerce Ltd.

SOURCE Emerge Commerce Ltd.

Continue Reading

Technology

John Overton High School student receives Humane Science Award from National Anti-Vivisection Society

Published

on

By

Parker Nunnery one of five young scientists from across the world to receive $3,000 prize at 2026 Regeneron International Science and Engineering Fair

NASHVILLE, Tenn., July 22, 2026 /PRNewswire/ — Parker Nunnery, a 2026 John Overton High School graduate, was one of just five recipients of the prestigious Humane Science Award presented by the National Anti-Vivisection Society (NAVS), a nonprofit devoted to the advancement of science without harming animals, at the 2026 Regeneron International Science and Engineering Fair (ISEF). Each award comes with a $3,000 prize to help the winners pursue humane scientific research projects.

Nunnery’s project, “Regulation of the PPARγ Pathway in Lung Cancer,” utilized both traditional cell cultures and advanced three-dimensional human cell-based models to study lung cancer. Investigating therapeutic compounds within these human-derived models allowed Nunnery to help advance cancer understanding and improve treatment strategies without using animals for her research.

Nunnery’s interest in research began at John Overton High School’s Interdisciplinary Science and Research (ISR) program, where she discovered a passion for cancer biology and connected with researchers at Vanderbilt University. Her project became personal when her teacher’s throat cancer diagnosis inspired her to pursue patient-focused treatments. Focusing on human-derived cellular models, she sought better ways to understand human diseases.

“Winning the NAVS Humane Science Award is incredibly exciting, and it was a great experience working alongside mentors like Dr. Greg Smith and Dr. Nicolas Means in the ISR program and with Dr. Amanda Linkous during my internship at Vanderbilt University,” said Nunnery. “Studying lung cancer using innovative human organoid models has inspired me to keep human health at the center of innovation in my future pursuits.”

This fall, Nunnery will attend Vanderbilt University to continue researching organoids, aging and cancer.

“Parker’s initiative aligns seamlessly with the mission of the NAVS Humane Science Award to foster scientific breakthroughs through non-animal methods,” said Dr. Lauren Stein, NAVS director of science and research programs. “This project highlights the vital role young researchers play in creating a more ethical, high-impact future for science. Parker is, without a doubt, a young scientist to watch.”

Two students from Florida and one each from Canada and South Korea also were selected as Humane Science Award winners for their projects among more than 1,300 submitted to ISEF. The competition drew more than 1,700 top-tier high school students from over 60 countries and territories to compete for over $7 million in awards, scholarships and internships and is the world’s largest pre-college science competition.

NAVS is the only animal advocacy organization invited to present an award at ISEF recognizing exceptional student projects that combine scientific excellence with humane, non-animal methods since 2002.

For more information about NAVS, visit navs.org.

To see the full list of the Regeneron ISEF 2026 Special Awards, visit societyforscience.org/press-release/regeneron-isef-2026-special-awards-ceremony/.

About NAVS

The National Anti-Vivisection Society (NAVS) is a U.S.-based nonprofit organization dedicated to ending the exploitation of animals used in scientific research and education. Founded in 1929, NAVS works to advance humane, human-relevant science through public education, policy advocacy and support for innovative non-animal research methods. The organization also promotes alternatives to classroom dissections and supports sanctuaries for animals formerly used in laboratories, helping drive the transition toward ethical and effective scientific practices. For more information about NAVS, visit navs.org.

View original content to download multimedia:https://www.prnewswire.com/news-releases/john-overton-high-school-student-receives-humane-science-award-from-national-anti-vivisection-society-302831317.html

SOURCE National Anti-Vivisection Society (NAVS)

Continue Reading

Technology

MetroTrade Partners with Devexperts to Launch Options on Futures Trading

Published

on

By

CHICAGO, July 22, 2026 /PRNewswire/ — MetroTrade, the U.S.-based futures broker for retail traders, has announced the launch of options on futures trading, in partnership with Devexperts, the global software developer for the capital markets.

MetroTrade, which provides low-cost market access offering some of the lowest commissions in the industry, will now offer both futures and options on futures through its platform in a single, integrated experience.

Following the launch, traders will be able to access CME-listed options on futures markets directly through the MetroTrader platform, including contracts tied to equity index, energy, metals, and more.

The new capabilities were delivered by Devexperts, MetroTrades’ technology partner. Founded in 2002, Devexperts specializes in developing multi-asset trading platforms, matching engines, exchange solutions, and market data delivery services for the global capital markets industry.

Working closely with MetroTrade, Devexperts developed a specialized options on futures solution complete with a comprehensive suite of options-specific features including options chain, earnings analyzer, and multi-leg options.

The addition of options on futures, which will be available within MetroTrader’s single account interface, will work to further enhance MetroTrade’s offering to futures traders in the U.S..

David Klotz, President of MetroTrade, says: “Devexperts has been a strong technology partner since the beginning, and that relationship made this possible. As their first client to bring options on futures to the platform, we worked closely with their team to build the infrastructure from the ground up. What we built together is the first options on futures trading experience of its kind on the platform.”

Jon Light, Senior Director of Product Management at Devexperts, says: “The addition of options on futures will provide MetroTrade’s traders with the opportunity to execute more advanced trading strategies with greater flexibility. We are pleased to have been able to work with MetroTrade to further enhance its already advanced offering to futures traders.”

About MetroTrade

Founded in 2023, MetroTrade is a U.S.-based futures brokerage built for retail traders. The company provides access to regulated futures markets through MetroTrader, its web and mobile trading platform. MetroTrade is a member of the National Futures Association (NFA) and operates under the regulatory oversight of the Commodity Futures Trading Commission (CFTC).

About Devexperts

Founded in 2002, Devexperts develops software for the capital markets with expertise in multi-asset trading platforms, matching engines, and exchange solutions. Learn more at: https://devexperts.com.

CONTACT: pr@devexperts.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/metrotrade-partners-with-devexperts-to-launch-options-on-futures-trading-302829609.html

SOURCE Devexperts

Continue Reading

Trending